All

Basel, Switzerland – 12 Nov, 2024, The BaseLaunch portfolio company Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and…

Synendos AG, a BaseLaunch portfolio company, has been awarded a prestigious grant under the Start-Up Innovation Project (SIP) scheme by Innosuisse. This highly competitive initiative…

Basel, Switzerland – 2 Oct, 2024, Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced yesterday…

MT-act spun out from the Institute of Human Genetics and CNRS in Montpellier, leverages recent advances in understanding cytoskeleton stiffness and its influence on age-related…

We’re pleased to announce a partnership with Hoffmann & Partner AG, a well-regarded firm specializing in mergers & acquisitions (M&A) and CFO services. With over…

We were pleased to have so many experts, partners, and friends joining the BaseLaunch Summer get-together on Wednesday last week. It was a great opportunity…

NXI Therapeutics AG, developer of tomorrow’s disruptive immunotherapies by coronin 1 modulation, today announces the extension of a pre-seed financing totalling to 3.5 million CHF.…

Cimeio Therapeutics today announced a publication in Nature showing that its CD45 antibody-drug conjugate (ADC) eradicated aggressive leukemic cells in vivo, while hematopoiesis was fully preserved and…

AbbVie joins other pharmaceutical, venture fund and biotechnology partners supporting BaseLaunch’s company creation endeavours. BaseLaunch’s mission is to help scientists and entrepreneurs build exceptional biotech…

Basel, Switzerland – 29 April, 2024, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today…